In Canada, a revolutionary clinical trial is taking place on patients who have suffered from heart attacks. According to the Windsor Star, the Ottawa Hospital Research Institute, the lead site for this investigation. There, after a patient is brought in for a heart attack, cells are taken from their blood and infused with extra copies of the endothelial nitric oxide synthase gene. This material helps boost boost blood vessel growth and helps tissues heal. They're then reintroduced back into the body through infusion. A patient's own cells are rejuvinated in order to fix the tissue that makes it hard for the heart to pump blood. The process is six days long. The researchers believe that this is the first trial in the world to test genetically boosted stem cells for this kind of treatment according to CTV News. The goal is to reach 100 patients over the next two years who have had a heart attack within 30 days of enrollment of the trial.This Fall at the Cell Therapy Bioprocessing Event, Jeffrey M. Karp, Ph.D., Associate Professor, Medicine, Brigham and Women’s Hospital, Harvard Medical School will be on hand to look at a similar type of cell regeneration - to enhance the engraftment and tracking of systemically infused stem cells through engineering the cell surface and through functionalizing cells with contrast agents and depots containing phenotype altering agents. For more information on this session and the rest of the agenda, download the brochure. If you'd like to join us in October 21-22, 2013 in Bethesda, Maryland, as a reader of this blog when you register to join us, you're eligible to save 20% off the standard rate when you mention the priority code B13188JP20.
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment